Twin Capital Management Inc. Purchases Shares of 1,226 Regeneron Pharmaceuticals, Inc. $REGN

Twin Capital Management Inc. purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,226 shares of the biopharmaceutical company’s stock, valued at approximately $689,000.

A number of other large investors have also recently made changes to their positions in REGN. Dodge & Cox lifted its holdings in Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after purchasing an additional 1,502,198 shares in the last quarter. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $628,151,000. Acadian Asset Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 234.7% during the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after buying an additional 326,583 shares in the last quarter. Loomis Sayles & Co. L P boosted its holdings in Regeneron Pharmaceuticals by 18.6% in the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after buying an additional 305,089 shares during the period. Finally, Invesco Ltd. increased its stake in Regeneron Pharmaceuticals by 26.5% in the 2nd quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after buying an additional 225,078 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $785.51 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The firm has a market capitalization of $82.56 billion, a P/E ratio of 18.90, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40. The company has a fifty day simple moving average of $757.29 and a two-hundred day simple moving average of $658.22. The company has a quick ratio of 4.22, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the company earned $12.07 EPS. The business’s revenue was up 2.5% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is 8.47%.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Wells Fargo & Company lifted their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $788.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.